Bayer's Biofuel Bet and Cancer Pipeline Face One Decisive Verdict in Missouri

Bayer balances Neste canola partnership and new drug approvals against an unresolved $7.25 billion Roundup settlement awaiting a Missouri court ruling.

Bayer is running two very different playbooks at once. On one side sits an agricultural partnership aimed at turning winter canola into a feedstock for renewable fuels; on the other, a pair of oncology and kidney-care approvals that are quietly reshaping the company's earnings mix. What ties the two together is a single unresolved question in a Missouri courtroom, where a proposed $7.25 billion settlement over Roundup litigation awaits final sign-off.

The stock has already priced in a good deal of optimism. At EUR 49.26, Bayer shares are up 33% since the start of the year, and Barclays gave the narrative fresh momentum last Friday by lifting its price target from EUR 60 to EUR 70 while keeping a buy rating. The 52-week high of EUR 53.86 remains the next technical marker bulls are watching.

The agricultural leg: canola as an energy feedstock

Bayer's cooperation with Neste centers on scaling "newgold®" winter canola as a raw material for biofuel production. For the Leverkusen-based group, the move represents a deliberate push to tilt its crop science portfolio toward lower-carbon value chains and the alternative fuels market — a segment where demand is growing but regulatory support can shift quickly.

The logic is straightforward: diversify beyond classic crop protection chemicals and position Bayer as a supplier to the energy transition. Commercial scaling projects of this kind can help stabilize organic growth in the division, though they require significant upfront investment before measurable returns materialize.

The pharmaceutical leg: two approvals, one filing

Bayer's drug pipeline has delivered a cluster of regulatory wins. Sevabertinib, marketed as Hyrnuo, received accelerated FDA approval last Thursday as an initial treatment option for adults with HER2-mutated non-squamous non-small cell lung cancer (NSCLC). Weeks earlier, Japan had already granted marketing authorization across all therapy lines.

Separately, roughly two weeks ago, Bayer filed for approval in Japan of Kerendia (finerenone) for non-diabetic chronic kidney disease, backed by positive Phase 3 data. The first-line designation for Hyrnuo matters commercially — it addresses a far larger patient population than a follow-on indication would, and it targets a group with substantial unmet medical need.

Where the two tracks collide

Both the biofuel partnership and the oncology rollout are designed to open new, higher-margin revenue streams. Whether they can do so fast enough to outrun Bayer's legal liabilities is the crux for investors.

The proposed class settlement over Roundup provides for payments of up to $7.25 billion, disbursed over as many as 21 years in declining, capped annual tranches. A hearing on final approval was held last Monday. No binding ruling has followed, which leaves the single largest overhang on the equity unresolved.

Reuters has reported that the outcome of this review will shape how the entire glyphosate litigation portfolio is handled going forward. Should the court reject the deal or demand material changes, Bayer would face a return to costly case-by-case litigation, with financial exposure that becomes difficult to model.

The bull case

In the optimistic reading, Hyrnuo ramps quickly into a dependable oncology revenue driver after its US and Japanese clearances, and the pending Kerendia filing broadens the pharma division's earnings profile further. Barclays sees the combination of operational momentum and gradual legal clarity as grounds for a push toward the EUR 70 mark.

On the agricultural side, scaling newgold® winter canola would let Bayer establish itself as a supplier to the energy transition beyond its traditional crop protection franchise. If the Missouri court confirms the $7.25 billion settlement without onerous conditions, a major slice of legal uncertainty would lift, potentially narrowing the valuation discount Bayer carries versus international peers and opening a path back toward the 52-week high of EUR 53.86.

The bear case

The dominant risk still sits in the United States. A failed or amended settlement would not only call the $7.25 billion figure into question but could send future financial obligations spiraling unpredictably. A rejection or significant delay would tie up the balance sheet further and crimp the room for investment in new projects.

Operational execution carries its own hazards. A commercial scaling agreement like the one with Neste has yet to prove itself in hard earnings, and establishing new agricultural feedstocks demands heavy upfront spending while biofuel market success depends on shifting regulatory frameworks. Hyrnuo's accelerated approval typically comes with requirements for confirmatory data down the line, and a drug clearance guarantees nothing commercially — the product must compete in the US market and negotiate reimbursement with payers. If Hyrnuo's revenue ramp stalls or the Kerendia filing in Japan slips, fixed obligations to retire legacy liabilities would meet a weaker-than-hoped cash inflow, and the recent share price recovery could evaporate.

What to watch

The near-term trajectory hinges on a clear dependency chain. As long as the Missouri review throws up no formal obstacles and expectations of an orderly resolution hold, operational progress from the Neste partnership and the Hyrnuo approval should underpin the fundamental valuation — a setup that argues for consolidation of recent gains.

If the settlement process before the Missouri court instead collapses, investors should brace for renewed valuation discounts and higher volatility, with the legal limbo pushing the agricultural and pharmaceutical initiatives back into the shadows.

The next hard test of operating performance arrives on November 3, 2026, when Bayer publishes its third-quarter report. That release will show how pharmaceutical sales are tracking in the current business and how management frames the financial burden for the remaining months. Until then, the Missouri ruling remains the decisive catalyst — the factor that determines whether Bayer can drive its transformation toward new fields like biofuel feedstocks with a freer balance sheet, or whether glyphosate keeps dictating the strategic agenda.